Further Observations on the Treatment of Hay Fever by Hypodermic Inoculations of Pollen Vaccine.

Freeman, John F.

doi:10.1016/s0140-6736(01)40417-x

Cited by 303 publications

(122 citation statements)

References 0 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…The route was started by Bostock who described hay fever, i.e., allergic rhinitis and that proved to be the one that Backley demonstrated to be caused by grass season [28]. The studies of immunotherapy by Noon (who died prematurely from a form of tuberculosis), were continued by the pioneer John Freeman [29,30]. It is necessary to remind readers that the use of antihistamines was reported in 1952 [31].…”

Section: From Subcutaneous Immunotherapy To Sublingual Immunotherapy:mentioning

confidence: 99%

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Lorenzo¹,

Leto-Barone²,

Piana³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

The lack of medication for allergy symptoms at the end of the last millennium has been the promoter of the idea of treating allergies as if you were treating an infectious disease, by vaccination prophylaxis. Two forms of AIT 1) subcutaneous immunotherapy (SCIT) and 2) sublingual immunotherapy (SLIT) are used in the world. Considerable interest has emerged in SLIT both scientifically and especially financially. SLIT is not a new treatment modality. First description dates back to 1900 when H. Curtis. It was relatively widely used until the late 1970's mainly in US by homeopathic therapists.A number of case series describing experience with the oral route were published during the 1920s and 1930s, but it seems to have been perceived not as efficacious nor as well tolerated as subcutaneous immunotherapy. The companies producing allergen immunotherapy have an alliance with important opinion leaders on both shores of the Atlantic.If SLIT did not work for 40 years, why should it work for respiratory allergic diseases today? This question is the mother of all questions in the field of respiratory allergic diseases. The purpose of this chapter is to provide past and current information about immunotherapy, and discuss controversies over efficacy and safety, and dosing considerations for SLIT to grass.

show abstract

Section: From Subcutaneous Immunotherapy To Sublingual Immunotherapy:mentioning

confidence: 99%

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Lorenzo¹,

Leto-Barone²,

Piana³

et al. 2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

show abstract

“…This notion arguably had its scientific foundation with Noon's and Freeman's description of a protocol to immunize subjects suffering from grass pollen-induced allergic rhinitis with an extract of grass pollen in order to reduce their clinical reactivity to that specific allergen. [1][2][3] Indeed, accurate diagnosis is foundational to the selection of optimal treatment in all areas of medicine. Accordingly, first identifying the allergen(s) and other factors which drive disease in individual allergic patients before attempting to define the most appropriate management and treatment for those patients represents one of the best examples of the critical importance of this general principle.…”

Section: Introductionmentioning

confidence: 99%

Toward precision medicine and health: Opportunities and challenges in allergic diseases

2016

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Abstract"Precision Medicine" (also called "Personalized", "Stratified" or "P4" Medicine) can be defined as the tailoring of preventive measures and medical treatments to the characteristics of each patient to obtain the best clinical outcome for each person while, ideally, also enhancing the costeffectiveness of such interventions for individuals and society. Clearly, the "best clinical outcome" in allergic diseases is not to get them in the first place. To emphasize the importance of disease prevention, a critical component of Precision Medicine can be referred to as "Precision Health", defined herein as the use of all available information pertaining to specific individuals (including family history, individual genetic and other biometric information, and exposures to risk factors for developing or exacerbating disease), as well as features of their environments, to sustain and enhance health and prevent the development of disease. In this article, I will provide a personal perspective on how the "Precision Health-Precision Medicine" approach can be applied to the related goals of preventing the development of allergic disorders and providing the most effective diagnosis, "disease monitoring", and care for those who suffer from these prevalent diseases. I will also mention some of the existing and potential challenges to achieving these ambitious goals.

show abstract

“…Allergen immunotherapy (AIT) has been an option for treating allergic diseases since it was initially described by Noon and Freeman over 100 years ago [1,2].…”

Section: Introduction Epidemiologymentioning

confidence: 99%

Novel Approaches of Immunotherapy

Stokes

Casale

2013

Curr Treat Options Allergy

View full text Add to dashboard Cite

Opinion statementAllergic diseases affect millions of adults and children in the United States. Allergen immunotherapy has been a treatment option for diseases such as allergic rhinitis, allergic asthma, and venom allergy for the last 100 years. In the last 25 years, alternative approaches to traditional subcutaneous immunotherapy have been developed. The purpose of these new therapies is two-fold: to improve safety and to improve the efficacy of allergen immunotherapy. Aluminum hydroxide has been used as an adjuvant to standard immunotherapy, but due to concerns about side effects, its use has been decreasing. The modification of allergens into allergoids has been an effective therapy in Europe, but at this time no preparations are available for use in the United States. Toll-like receptors have demonstrated mixed results with early trials in the United States, showing promise with the use of a TLR4 agonist, while a TLR9 agonist had disappointing results. Early studies with the use of virus-like particles with and without allergens have shown additional promise, and further trials are currently underway. These novel approaches may improve the immunologic response and often the clinical outcomes for the management of allergic diseases.

show abstract

Further Observations on the Treatment of Hay Fever by Hypodermic Inoculations of Pollen Vaccine.

Cited by 303 publications

References 0 publications

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Unmet Needs in Understanding Sublingual Immunotherapy to Grass Pollen

Toward precision medicine and health: Opportunities and challenges in allergic diseases

Novel Approaches of Immunotherapy

Contact Info

Product

Resources

About